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Modulation of Rab7a‑mediated 
growth factor receptor trafficking 
inhibits islet beta cell apoptosis 
and autophagy under conditions 
of metabolic stress
Nirun V. Hewawasam1,4, Fadel Lhaf1,4, Henry A. Taylor1, Katrina Viloria1, Amazon Austin2, 
Aileen King2, Peter Jones2, Lucy Jones1, Mark D. Turner3 & Natasha J. Hill1*
Regenerative medicine approaches to enhancing beta cell growth and survival represent potential 
treatments for diabetes. It is known that growth factors such as insulin, IGF‑1 and HGF support beta 
cell growth and survival, but in people with type 2 diabetes the destructive effects of metabolic stress 
predominate and beta cell death or dysfunction occurs. In this study we explore the novel hypothesis 
that regulation of growth factor receptor trafficking can be used to promote islet beta cell survival. 
Growth factor signalling is dependent on the presence of cell surface receptors. Endosomal trafficking 
and subsequent recycling or degradation of these receptors is controlled by the Rab GTPase family 
of proteins. We show that Rab7a siRNA inhibition enhances IGF‑1 and HGF signalling in beta cells 
and increases expression of the growth factor receptors IGF‑1R and c‑Met. Furthermore, Rab7a 
inhibition promotes beta cell growth and islet survival, and protects against activation of apoptosis 
and autophagy pathways under conditions of metabolic stress. This study therefore demonstrates 
that Rab7a‑mediated trafficking of growth factor receptors controls beta cell survival. Pharmaceutical 
Rab7a inhibition may provide a means to promote beta cell survival in the context of metabolic stress 
and prevent the onset of type 2 diabetes.
There are currently 382 million people affected by diabetes, with this figure estimated to reach 592 million by 
 20351. Loss or insufficiency of insulin producing beta cells is a causative factor in both type 1 and type 2 diabetes. 
In type 1 diabetes beta cells are destroyed by autoreactive immune cells, while in type 2 diabetes the number or 
function of beta cells is compromised and insulin production is insufficient to cope with  demand2,3. In type 2 dia-
betes, the inflammatory and metabolic conditions, including high circulating levels of saturated fatty acids, place 
a particular stress on beta cells that contributes to their  demise4. Therefore, regenerative medicine approaches to 
enhancing beta cell growth and survival represent potential treatments for diabetes.
There are many factors known to regulate islet growth in the adult pancreas, including growth factors, amino 
acids, glucose, insulin and gestational  hormones5–8. Both insulin-like growth factor-1 (IGF-1) and hepatocyte 
growth factor (HGF) have been shown to increase islet beta cell proliferation in vivo and in vitro9–12. Loss of HGF 
signalling in pancreatic beta cells inhibits beta cell survival and accelerates the onset of diabetes, and can similarly 
cause gestational diabetes and incomplete maternal beta cell  adaptation10,13. There is a complex cross-talk between 
IGF-1, insulin and the IGF-1 and insulin receptors that is challenging to unravel in vivo, but it is clear that the 
combined loss of insulin and IGF-1 receptors in beta cells results in  diabetes14. In terms of intracellular signalling, 
HGF signals through the cMET receptor to activate multiple signalling pathways including Ras-ERK and P13K/
Akt15. IGF-1 binding to IGF-1R similarly signals through multiple pathways including PI3K-mammalian target 
of rapamycin (mTOR), as well as activating Ras-ERK16. However, although much is now known about the role 
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of growth factors in regulating islet beta cell proliferation, it has not yet proved possible to sufficiently promote 
islet expansion for therapeutic use.
Growth factor responses are dependent upon the presence of growth factor receptors at the cell surface. Cell 
surface receptor density can be increased by de novo synthesis of receptors, by recycling from intracellular stores 
or by preventing receptor internalisation. Growth factor receptors can also activate distinct signalling pathways 
depending on their localization at either the cell surface or in  endosomes17. The regulation of growth factor 
receptor trafficking is therefore critical in the regulation of cellular growth and survival.
Rab GTPases mediate vesicular transport events and play a primary role in the regulation of receptor traf-
ficking. Rab proteins regulate both biosynthetic and endocytic pathway trafficking, including the degradation 
and recycling of surface receptors, and thus regulate cell growth and  differentiation18. Following initial endo-
cytosis, cell surface receptors in early endosomal vesicles are sorted into divergent pathways, entering either a 
fast recycling pathway dependent on Rab4, a slow recycling pathway dependent on Rab11, or the lysosomal 
degradation pathway dependent on  Rab7a19. In haematopoetic cells, inhibiting Rab7a prevents trafficking of 
nutrient transporter proteins to the lysosome following growth factor withdrawal. Instead, nutrient receptor 
expression at the cell surface is maintained, promoting cell  survival20. Rab7a also regulates trafficking of EGFR, 
the NGF receptor Trk1, and the angiogenic receptor  Nrp121–23, and is essential for the process of  autophagy24,25. 
Together, these studies suggest the possibility that Rab7a inhibition could be used therapeutically to promote 
growth factor responsiveness.
Here, we test the hypothesis that Rab7a inhibition can be used to increase growth factor receptor density in 
beta cells in order to enhance growth factor responses, and that this could be used to promote beta cell survival 
for the treatment of diabetes.
Materials and methods
Islet isolation and culture. Pancreatic islets were isolated from ICR mice aged 8–12 weeks (Harlan, Hunt-
ingdon UK). All experimental protocols were approved by the animal welfare and ethical review board at King’s 
College London and in accordance with the UK. Home Office Animals (Scientific Procedures) Act 1986 with 
2012 amendments (establishment licence: X24D82DFF; project licence: PBCFBE464). Islets were isolated using 
collagenase digestion and separated by density gradient centrifugation as previously  described26. After washing, 
islets were handpicked and cultured overnight in RPMI medium containing 11.1 mM d-glucose and addition-
ally supplemented with 10% foetal bovine serum (FBS), Penicillin (100 units/ml) and streptomycin (100 µg/ml).
Cell culture. All cell culture reagents were purchased from Gibco Life Technologies unless otherwise stated. 
Insulinoma-1 (INS-1) cells were obtained from Dr E.C. Edling, Queen Mary University of London, and grown in 
Roswell Park Memorial Institute (RPMI) 1640 medium containing 11.1 mM d-glucose and 2.1 mM l-glutamine 
supplemented with 10% heat-inactivated FBS, 2 mM l-glutamine, 10 mM HEPES (pH 7.2–7.5), 1 mM Sodium 
Pyruvate, Penicillin (100 units/ml), streptomycin (100 µg/ml) and 0.05 mM 2-mercaptoethanol (Sigma). Cells 
were grown in T75 flasks (Nunc/Fisher Thermo Scientific) at 37 °C under 5%  CO2 and passaged every 3–4 days 
using 0.05% Trypsin EDTA. Experiments were performed within ten passages. Insulin expression by imunocy-
tochemistry was used to authenticate beta cell status. Mycoplasma status has not been tested.
For experiments involving growth factor treatment, lyophilised IGF-1 or HGF (R&D Systems) was re-sus-
pended according to the manufacturer’s instructions at 100 μg/ml in sterile PBS. Following Rab7a knockdown, 
INS-1 cells (1 × 105 cells/well in 48 well plate) and islet cells were starved overnight in low serum medium (0.5% 
or 0% FBS as indicated). For islets, 60 islets per treatment were typically used, and islets were dispersed into 
single cells using Accutase treatment. The cells were then stimulated with either IGF-1 or HGF (20 or 200 ng/
ml as indicated) in low serum medium for between 0 and 60 min.
Immunohistochemistry. Whole mouse pancreas was removed, fixed in 10% Neutral Buffered Forma-
lin (NBF) (pH 6.8–7.2) for 24 h and embedded in paraffin. Sections (5 μm) were de-paraffinised using Histo-
clear (AGTC Bioproducts), incubated with PBS and 0.3% Triton X-100 (Sigma) and blocked with 10% normal 
horse serum (Sigma). For Rab7a staining, tissue sections were incubated overnight at 4 °C with Rab7a antibody 
(Abcam ab137029, diluted 1/25–1/100 in 10% normal horse serum. The following day slides were incubated 
with goat anti-rabbit biotinylated secondary antibody (Vector Laboratories-BA1000; diluted 1/250) for 90 min at 
ambient temperature. Non-specific activity of endogenous peroxidase activity was minimised by pre-treatment 
of slides with 1% hydrogen peroxide for 15 min. For visualisation, the ABC/DAB system was used according 
to the manufacturer’s instructions (Vector Laboratories). Sections were counter stained with haematoxylin and 
visualised using a Nikon Eclipse 80i microscope and NIS element software.
Fluorescence immunocytochemistry. For Rab7a staining, INS-1 cells (2 × 105 cells/well) were grown 
on poly-lysine coated coverslips and fixed in 10% NBF, then incubated with Rab7a primary antibody (1/1000; 
Abcam, ab137029) followed by secondary Alexa Fluor 488 secondary antibody (1:200; Invitrogen 10256302). 
SlowFade Gold Antifade DAPI (Thermo Scientific) was used to mount coverslips and visualise nuclei. Slides 
were viewed using a Leica TCS AOBS inverted laser scanning confocal microscope and X63 oil immersion 
objective. All images within a single experiment were obtained and processed under identical settings.
For growth factor receptor staining, INS-1 cells (2 × 105 cells/well) were grown on poly-lysine coated cover-
slips in a six well plate. Following Rab7a knockdown, cells were fixed in 10% NBF and washed using cold PBS 
containing  Ca2+ and  Mg2+. To minimise non-specific binding cells were blocked using 10% normal horse serum 
for 1 h at room temperature followed by overnight incubation at 4 °C with IGF-1R and c-Met primary antibodies 
(both diluted 1:250, IGF-1R 9750S Cell Signaling Technology; c-Met SC-162R Santa Cruz Biotechnology). The 
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next day, cells were washed and treated with Alexa Fluor 488 secondary antibody (1:350) and Cell Mask Orange 
(Invitrogen VXC10045) to stain the plasma cell membrane. Coverslips were mounted onto slides using SlowFade 
Gold Antifade with DAPI. Images were captured using a 63× oil immersion objective on a Leica TCS SP2 AOBS 
inverted laser scanning confocal microscope. All images in a single experiment were taken and processed using 
identical settings. Quantification of receptor expression was performed using ImageJ. Binary images were created 
for each green channel image using a constant threshold, and the pixel number above this threshold measured 
for each image. To standardise for variability in the number of cells, the number of cells/image was quantified 
using the DAPI stain and the Analyse Particles function in  ImageJ27.
For the Caspase-3/7 apoptosis assay, cultures were supplemented with 5 µm non-fluorescent caspase − 3/− 7 
substrate (DEVD) that releases a green DNA binding fluorescent label upon caspase activation and cleavage 
(Essen Bioscience). Apoptotic cells therefore fluoresce. An IncuCyte Zoom Live Cell Imaging System was used 
for image capture and analysis.
siRNA transfection. For siRNA knockdown, cells were treated with either Rab7a siRNA (ON-TARGET-
plus Rat Rab7aa siRNA J-089334-09-0010, sequence GUA AAG AGA UGA GCG UGA U; ON TARGETplus mouse 
Rab7a siRNA D-040859-01, sequence CAG CUG GAG AGA CGA GUU U); or with a control siRNA (ON-TAR-
GETplus non-targeting D-001810-10), all purchased from Dharmacon and re-suspended at 100 μM according 
to the manufacturer’s instructions. INS-1 cells were plated in six well plates at 1 × 105 cells/well and immediately 
transfected for 3 days with the indicated concentration of siRNA using 3 μl/ml Hiperfect transfection reagent 
(Qiagen). For experiments using pancreatic islets, islets were allowed to recover for 24 h post isolation then 
washed in PBS and centrifuged at 178 × g (1000 rpm) for 3 min. After discarding the supernatant, the islets were 
incubated in a gentle dissociation solution containing 0.02% EDTA in PBS, for 1.5 min at 37 °C, as previously 
 described28. Islets were then washed in complete medium, centrifuged at 178Xg for 3 min and cultured in low-
serum medium containing 0.5% FBS for 2 h before transfection with 150 nM Rab7a siRNA or control siRNA 
complexes in 3 μl/ml Hiperfect transfection reagent. Islets were transfected for 3 days then used for downstream 
experiments and to confirm Rab7a knockdown by Western blot. For all experiments in this manuscript Rab7a 
knockdown was at least 70% compared to control siRNA treated cells except where otherwise indicated.
Western Blot. Cells were washed with ice cold PBS and lysed with RIPA buffer (Pierce/Thermo Fisher Sci-
entific 89900). SDS sample buffer was added to each sample (1:5 dilution) prior to boiling at 100 °C for 6 min. 
For INS-1 cells, typically 10 µg protein was loaded per well, and for islets the entire lysate from 60 dispersed 
islets was used. Lysates were resolved by SDS-PAGE using 13% gel and the proteins were electro-transferred onto 
nitrocellulose membranes (GE Healthcare). Intact membranes were blocked in 5% non-fat milk followed by 
overnight incubation at 4 °C with primary antibodies. The following primary antibodies were used in this study: 
Rab7a (1:1000; Abcam ab137029 or Cell Signaling Technology 9367), β-actin (1:4000; Abcam ab8224), β-tubulin 
(1:1000; Abcam ab6046 or Cell Signaling Technology 2128), p-ERK 1/2 (1:1000; Cell Signalling 9101S), rabbit 
anti-Met (Santa Cruz SP260), rabbit anti-LC3-A/B (Cell Signalling Technology 4108) and rabbit anti-Caspase-3 
(Cell Signalling Technology 9662). The following day membranes were incubated with horseradish peroxidase-
conjugated anti-rabbit secondary antibody (1:2500; Cell Signaling 7074). Proteins were visualised using Super-
signal West Pico chemiluminescent substrate (Thermo Fisher Scientific) and a Syngene GeneGnome imaging 
system with GeneSnap software. Band intensities were quantified using ImageJ  software27. Lanes have in some 
cases been re-ordered for clarity (indicated by line in blot). Images of the original, uncropped blots are available 
as “Supplementary data”, with the exception of the validation experiments in Fig. 4c,d, Supplementary Fig. 1, and 
for beta tubulin in Fig. 6c, where whole blot images could not be located.
Sulphorhodamine B (SRB) assay. The SRB assay is a colourimetric assay that indirectly measures cell 
number by quantification of  protein29,30. INS-1 cells treated with Rab7a or control siRNA were re-plated at 1 × 104 
cells/well in a 96 well plate. Cells were starved overnight in medium containing 0.5% FBS, then stimulated with 
20 ng/ml IGF-1 or HGF. Some cells were treated with 20 ng/ml etoposide, or cultured in low serum (0.5% FBS) 
or complete (10% FBS) media. On day 5 of treatment cells were fixed using 40% w/v TCA (Thermo Scientific 
10336200) at a final concentration of 10% v/v at 4 °C for 1 h and washed using water. Once sufficiently dry, pro-
teins were stained using 0.4% w/v SRB (Sigma S1402) in 1% v/v acetic acid for 30 min at ambient temperature 
and washed using water. After sufficient drying 10 mM Tris at pH 10 was added to solubilise SRB and absorbance 
was read at 565 nm using an Epoch Microplate spectrophotometer (Bio Tek, USA).
Live/dead assay. The LIVE/DEAD Viability/Cytotoxicity kit for mammalian cells (Thermo Scientific 
L-3224) was used to visualise and quantify the % live dispersed islet cells. Following Rab7a knockdown islets 
from 6 mice were divided equally into groups of 60 islets and incubated with Accutase (Sigma Aldrich) for 
10 min at 37 °C for dispersion. Following de-activation of Accutase using complete medium, the dispersed islets 
were seeded onto poly-lysine coated coverslips, allowed to adhere overnight. The islet cells were then serum-
starved for 12 h before treatment with serum free medium, or serum free medium containing 200 ng/ml IGF-1 
and. After 2 days coverslips were stained with Calcein AM (0.25 μM) and Ethidium homodimer-1 (2.0 μM) at 
ambient temperature for 1 h under reduced light. Coverslips were then mounted onto glass slides and islet cells 
viewed using 40× and 63× oil immersion objectives on a Leica TCS SP2 AOBS inverted laser scanning confocal 
microscope. Six images were taken per coverslip, and two coverslips imaged per treatment in each experiment.
Palmitic acid preparation and treatment. Palmitic acid solutions were prepared according to pub-
lished  protocols31. Briefly, 25.642 g of palmitic acid (PA) (Sigma P-500) was dissolved in 1 l of 0.1 M Sodium 
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Hydroxide (NaOH) at 70 °C to obtain a stock 100 mM PA solution. In a 60 °C water bath, 5% (wt/vol) free fatty 
acid (FFA)-free bovine serum albumin (BSA) (Sigma A-6003) was prepared in serum-free RPMI medium. A 
stock solution of 5 mM PA/BSA complex was prepared by repeated vortexing followed by 60 °C incubation, then 
allowed to reach room temperature before sterile filtration (0.45 μm pore; Sigma N9020). This 5 mM PA/BSA 
solution was further diluted in RPMI-1640 to achieve the indicated final concentration. The solution was stored 
at − 20 °C for 3–4 weeks. Control cells were treated with a solution prepared identically except for the absence 
of PA.
Live cell imaging. To visualise and compare the effect of palmitic acid on cell density and apoptosis, the real 
time live- cell imaging system IncuCyte Zoom (Essen Bioscience) was used. For these experiments INS-1 cells 
were transfected as above but in a 96 well format with 10,000 cells per well. The IncuCyte Caspase-3/7 reagent 
for apoptosis (cat. 4440) was diluted in culture medium to a final concentration of 5 µM (1:1000) and added to 
the wells with the palmitic acid. Data was then collected at 72 h. Confluency and number of apoptotic cells were 
determined using IncuCyte software (version 2015A).
Statistical analysis. Data processing was performed as indicated in the relevant sections, and the num-
ber of replicates for each experiment is indicated in the relevant figure legend. The sample size was chosen to 
determine consistency of the results. Results are indicated as mean ± standard error of the mean (SEM) unless 
otherwise indicated. A two-tailed Students’ t-test was used for statistical analysis, and in all cases, p ≤ 0.05 was 
accepted as significant.
Results
Expression of Rab7a in pancreatic islets and beta cells. Using immunohistochemistry, we show that 
Rab7a is expressed throughout the pancreas including islet cells, acinar tissue, ducts and blood vessels (Fig. 1a). 
Fluorescence immunocytochemistry further revealed the subcellular localisation of Rab7a within the cytoplasm 
of INS-1 cells, with a punctate distribution consistent with the expected localisation in a late endosomal/lyso-
somal compartment (Fig. 1b). Rab7a expression could also be detected in INS-1 cells by western blot, and a 
titration of siRNA concentration showed that at least 80 nM Rab7a siRNA was required to reduce Rab7a protein 
expression, with maximal knockdown (98%) achieved using 150 nM siRNA (Fig. 1c). Subsequent experiments 
therefore utilized 150  nM siRNA and, although the extent of knockdown varied, 150  nM siRNA treatment 
reduced Rab7a expression by on average over 70%, as shown in Fig. 1d.
Rab7a siRNA knockdown enhances beta cell growth. To determine the effect of reducing Rab7a 
expression on beta cell growth, we investigated the effect of Rab7a siRNA knockdown in response to two impor-
tant beta cell growth factors, IGF-1 and HGF. INS-1 cells were transfected with either control- or Rab7a-siRNA, 
re-plated at 10,000 cells/well and cultured overnight in reduced serum medium. The cells were then stimulated 
for 5 days with 20 ng/ml IGF-1 or HGF, with the cytotoxic compound etoposide (as a negative control), or left 
untreated. As shown in Fig. 2a, Rab7a siRNA transfected cells showed enhanced growth in response to both 
HGF and IGF-1 compared to control siRNA transfected cells. These experiments demonstrate that Rab7a inhibi-
tion enhances beta cell growth.
Rab7a siRNA knockdown enhances growth factor signalling in beta cells. ERK 1/2 activation 
is one of the key signalling events involved in beta cell growth and  proliferation32–34. In order to test whether 
the enhanced beta cell growth was due to increased growth factor receptor signalling, we therefore determined 
the effect of Rab7a siRNA treatment on ERK-1/2 activation following growth factor treatment. As shown in 
Fig. 2b,c, 20 ng/ml IGF-1 or HGF was sufficient to cause a 5–8-fold increase in ERK 1/2 phosphorylation, with 
peak activation being observed at 5 min and signal termination occurring by 60 min. We then determined the 
effect of Rab7a knockdown on IGF-1 and HGF induced signalling. INS-1 cells treated with Rab7a siRNA or 
control siRNA were re-plated on day 3 and cultured overnight in reduced serum medium. The cells were then 
stimulated with IGF-1 or HGF, and ERK1/2 phosphorylation was determined by Western blot. ERK1/2 phos-
phorylation was increased by approximately 2-fold in Rab7a knockdown cells compared to control cells after 
15 min stimulation with both IGF-1 and HGF (Fig. 2d,e). This increased signalling suggests that Rab7a knock-
down enhances growth factor responsiveness.
Figure 1.  Expression of Rab7a in mouse pancreas and in beta cells. (a) Paraffin embedded mouse pancreas 
sections were immunostained using Rab7a antibody (brown; top panels) or with the secondary antibody only 
as a control (lower panels), and counterstained with haematoxylin. Images taken using a 20× objective and 
scale bar = 50 μm. Staining representative of three independent experiments. (b) INS-1 cells were grown on 
coverslips and fixed before staining with a Rab7a antibody (green) or with the Alexa 488 secondary only. Nuclei 
were stained with DAPI (blue). Images were taken using a 63× objective and scale bar = 10 μm. Staining is 
representative of multiple images taken from three slides. (c) INS-1 cells were treated in an initial experiment 
with a range of concentrations of Rab7a siRNA or negative control siRNA, or left untransfected. On day 3 of 
culture, cells were lysed and analysed by Western blot with antibodies to Rab7a and β tubulin as a loading 
control. (d) Quantification of Western blot detection of Rab7a expression in INS-1 cells treated with 150 nM or 
control or Rab7a siRNA. The graph indicates mean Rab7a expression ± SEM, n = 5 independent experiments; 
values are standardised to β tubulin and relative to control siRNA. Students’ t-test was used to evaluate statistical 
significance.
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Rab7a siRNA knockdown increases growth factor receptor density in beta cells. Rab7a medi-
ates the trafficking of internalised receptors for  degradation35,36. Having shown that Rab7a siRNA knockdown 
enhances growth factor receptor signalling, we therefore investigated whether this could be explained by an 
increase in growth factor receptor density. Rab7a siRNA and control treated cells were grown on coverslips and 
receptor expression was determined by quantitative confocal microscopy. As shown in Fig. 3, the expression 
of IGF-1R and the HGF receptor c-Met was significantly increased in Rab7a siRNA treated cells compared to 
control siRNA treated cells. This difference is clearly represented in the binary images of the green channel after 
thresholding, as well in the quantified data. The increased expression of c-Met following Rab7a siRNA knock-
down was further confirmed by western blot (Fig. 3e,f). These experiments suggest that the enhanced respon-
siveness to growth factors caused by Rab7a knockdown is a result of increased growth factor receptor density.
Rab7a knockdown in mouse islets enhances IGF‑1 induced cell signalling. Having demonstrated 
that Rab7a enhances growth factor responsiveness in INS-1 cells, we then tested whether the same effect can 
be seen in primary mouse islets. Initial validation experiments demonstrated that pre-treatment with  EDTA28 
allowed us to reduce Rab7a expression up to or above the 70% threshold used in beta cells using 150 nM Rab7a 
siRNA (Fig.  4a,b). Validation of the optimal conditions for IGF-1 activation of ERK 1/2 signalling in islets 
showed that 200 ng/ml IGF-1 induced strong ERK-1/2 phosphorylation (Fig. 4c), and that peak activation in 
intact islets was observed at 7.5–10 min (Fig. 4d). Using these optimised conditions, we then tested the effect of 
Rab7a siRNA knockdown on IGF-1 signalling in islets. Islets transfected with control or Rab7a siRNA for 3 days 
were then cultured overnight in low serum medium before stimulation with 200 ng/ml IGF-1. As shown in 
Fig. 4e,f, ERK-1/2 phosphorylation was increased more than three-fold at 7.5 min, consistent with the effect seen 
previously in INS-1 cells. Rab7a inhibition therefore enhances growth factor signalling in primary mouse islets.
Rab7a knockdown enhances growth factor induced islet survival. Since the proliferative rate of 
beta cells in primary islets is very low, in order to test whether Rab7a knockdown affects growth factor respon-
siveness at the functional level we used a previously validated islet survival assay in which growth factor respon-
siveness is measured by the ability of growth factors to rescue islets from cell death induced by low serum 
 conditions26. Islets were treated either with control- or Rab7a-siRNA as above, then dispersed into single cells 
and adhered to coated coverslips. Once adhered, the cells were serum starved for 12 h, then stimulated with or 
without IGF-1 for 2 days. Islet cell survival was then determined using a fluorescent live/dead assay. As expected, 
in control siRNA cells the presence of IGF-1 induced a two-fold increase in islet survival (Fig. 5a,b). However, 
this effect was dramatically enhanced in Rab7a siRNA treated cells, where a greater than 5-fold increase in islet 
survival was observed in response to IGF-1 treatment. Islet survival in response to growth factor treatment 
is therefore significantly greater in Rab7a siRNA treated cells compared to cells treated with control siRNA. 
This is consistent with the increase in growth factor signalling observed in Rab7a siRNA treated islets, and the 
enhanced growth in response to IGF-1 observed in INS-1 cells, and demonstrates that Rab7a inhibition is able 
to rescue beta cell loss resulting from low serum-stress, and enhances islet survival.
We also performed similar experiments in intact islets, rather than with single cells as before, and again saw 
enhanced responsiveness to IGF-1 in terms of increased survival in Rab7a siRNA treated islets (Fig. 5c). In these 
experiments we also performed additional controls, in which control- and Rab7a-siRNA treated islets did not 
undergo serum starvation and were instead maintained in standard 10% FBS conditions. Importantly, in the 
absence of serum-stress Rab7a knockdown did not significantly affect islet survival, suggesting that it is only 
under conditions of cellular stress that Rab7a has a significant affect in promoting islet survival.
Rab7a siRNA knockdown protects against metabolic stress‑induced autophagy and apopto‑
sis.. The capacity for beta cells to withstand metabolic stress is thought to be critical in avoiding the develop-
ment of type 2 diabetes. We therefore examined whether Rab7a attenuation can protect against metabolic stress. 
INS-1 cells were treated with varying concentrations of palmitic acid, a saturated fatty acid known to be lipotoxic 
to beta cells and often present at high levels in people with type 2  diabetes37. Palmitic acid treatment was seen to 
induce expression of both autophagy (expression of LC3-II) and apoptosis (caspase-3 cleavage) in INS-1 cells, as 
Figure 2.  Rab7a siRNA knockdown enhances IGF-1 and HGF growth and signalling in beta cells. (a), INS-1 
cells were transfected with 100 nM Rab7a siRNA or control siRNA for 3 days, re-plated at 1 × 104 cells/well and 
cultured overnight in reduced serum medium. The cells were then stimulated with 20 ng/ml IGF-1, HGF or 
etoposide, or left untreated, and the SRB assay was performed on day 5 to determine cell growth. Graphs show 
mean fold change relative to control (0.5% FBS) treated cells ± SEM (n = 3; data represents three independent 
experiments with n = 8 replicates in each experiment). Statistical analysis in was performed using Students’ 
t-test. In (b–e) Western blot analysis was performed to determine activation of the signalling intermediate 
phospho-ERK-1/2 following overnight culture in low serum medium (0.5% FBS) and treatment with growth 
factor as indicated. Validation of conditions required for ERK-1/2 phosphorylation by IGF-1 (b) and HGF (c) 
in INS-1 cells was determined by treating with either 20 or 200 ng/ml growth factor for the indicated times 
(representative of two independent experiments; validation data). In (d, e), INS-1 cells were transfected with 
control- or Rab7a-siRNA before stimulation with 20 ng/ml IGF-1 (d) or HGF (e). Values indicate phospho-ERK 
1/2 expression standardised to β-tubulin and relative to unstimulated cells. Results are representative of three 
independent experiments with similar timepoints.
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shown in Supplementary Fig. 1. In the absence of palmitic acid, Rab7a siRNA knockdown did not have a signifi-
cant effect on either autophagy or apoptosis markers, as shown in Supplementary Fig. 2. This further supports 
our observations above that Rab7a only affects beta cells under conditions of cellular stress.
We therefore tested the effect of palmitic acid-induced metabolic stress under conditions of Rab7a knock-
down. As expected, in control siRNA-treated cells palmitic acid caused beta cell loss, with activation of both 
apoptosis (caspase-3/7 activation) and autophagy (expression of LC3-II) pathways, as shown in Fig. 6. However, 
Rab7a siRNA treatment inhibited this metabolic-stress induced beta cell loss and also inhibited the activation 
of both apoptotic and autophagic pathways, suggesting that attenuation of Rab7a promotes beta cell survival 
under conditions of metabolic stress.
Discussion
In this study we have explored the novel hypothesis that regulation of growth factor receptor trafficking can be 
used to promote islet survival. We have shown for the first time that Rab7a regulates IGF-1 and HGF signalling, 
and that Rab7a inhibition enhances IGF-1R and c-Met receptor levels. Furthermore, our data demonstrates that 
inhibition of Rab7a can be used to enhance beta cell growth factor responsiveness and to promote islet survival 
under conditions of metabolic stress relevant to the conditions that occur in many people with type 2 diabetes.
It has been shown elsewhere that Rab7a is necessary for trafficking of cargo from late endosomes to 
 lysosomes36. Although not directly tested here, it is therefore likely that Rab7a siRNA inhibition delays or pre-
vents lysosomal degradation of IGF-1R and c-Met receptors, thereby causing the increased growth factor recep-
tor density that we observe and conferring enhanced growth factor responsiveness. Delayed degradation could 
either promote receptor recycling via Rab4/Rab11 recycling pathways, resulting in reinsertion of receptors in the 
plasma membrane and increasing signalling at the cell surface; or, alternatively, could result in receptor accumu-
lation in an endosomal compartment. Indeed, previous studies using Rab7a siRNA suggested that while Rab7a 
inhibition causes endosomal accumulation of EGFR, it also promotes receptor recycling of unliganded receptors 
to the cell surface via the slow peri-nuclear recycling  pathway38. Another study has shown that Rab7a siRNA 
treatment decreases lysosomal trafficking of the Nrp1 receptor to enhance angiogenesis and, consistent with our 
experiments in beta cells, also suggests that Rab7a siRNA inhibition promotes growth factor  responsiveness23. 
In the light of these findings, our data suggests that Rab7a siRNA treatment enhances islet survival by increas-
ing pro-survival growth factor signalling from either an endosomal compartment, or by promoting receptor 
recycling to the cell surface.
Interestingly, the experiments used in our study involve either serum-starvation prior to growth factor treat-
ment, or mimic the metabolic stress conditions associated with type 2 diabetes using high levels of palmitic acid. 
It is known that serum-starvation and other conditions of cellular stress result in the activation of a co-ordinated 
programme of stress responses, including both autophagic degradation of cytoplasmic components and the 
endocytic degradation of cell surface  receptors39. These two pathways converge at the point of lysosomal  fusion40. 
Rab7a is known to regulate both autophagy and the endocytic pathways, and Rab7a is itself activated by cell 
 stress20,24,41. This has important implications since in type 2 diabetes islet beta cells are subject to stressful condi-
tions due to high levels of fatty acids and glucose, as well as endoplasmic reticulum stress due to high secretory 
activity as a result of increased insulin  demand42. Islet transcriptomic studies have previously shown that IGF-1R 
is downregulated by both metabolic and inflammatory cytokine  stress43,44. Therapeutic inhibition of Rab7a may 
therefore be particularly effective in protecting islet beta cells under the conditions of metabolic stress that exist 
in many diabetes patients, since in other cell types and under normal conditions the majority of endosomal cargo 
is recycled to the plasma membrane and lysosomal degradation of growth factor receptors is  low40. Consistent 
with this, our data suggests that the effects of Rab7a inhibition in non-stressed cells are very limited, conferring 
specificity to struggling beta cells. The lack of enhanced growth factor responsiveness in unstressed cells also 
suggests that Rab7a inhibition is effective in preventing the degradation of growth factor receptors during cellular 
stress, with positive effects on islet survival, but does not promote a potentially dangerous accumulation of growth 
factor receptors under ‘normal’ conditions. The endocytic pathway is highly conserved across species. Therapeutic 
Rab7a inhibition to maintain growth factor receptor density and subsequent growth factor responsiveness to 
protect islets may therefore be an effective approach to enable beta cells to survive the metabolic stress they are 
Figure 3.  Rab7a siRNA knockdown increases growth factor receptor density in beta cells. INS-1 cells were 
plated on coverslips and transfected with control- or Rab7a-siRNA for 3 days. Cells were then fixed and 
stained with antibodies to IGF-1R (a, b) or the HGF receptor c-Met (c, d), shown in green, and with Cell Mask 
Orange. Representative images are shown in (a) and (c). Scale bar = 30 μm. Quantification of receptor staining 
was determined by calculating the green pixel number over the set threshold, as shown in the binary images, 
and standardised for the number of cells/image determined using DAPI staining and the cell count function 
in ImageJ. Graphs show mean pixel number ± SEM for IGF-1R (b) and c-Met (d). n = 8 for both IGF-1R and 
c-Met experiments, and data is pooled from three independent experiments. Statistical analysis was performed 
using Students’ t-test. Secondary only controls were negative for green fluorescent staining (data not shown). 
(e, f) INS-1 cells were treated with either control- or Rab7a-siRNA for 3 days, cell lysates were then prepared 
and analysed by western blot using the indicated antibodies. A representative blot is shown in (e), and mean 
c-Met receptor band intensity ± SEM for four independent experiments is shown in (f). Statistical significance 
was determined using Student’s paired sample t-test. Rab7a siRNA knockdown was on average ~ 50% in the 
experiments shown in (e, f) and therefore did not reach the threshold of 70% used in the rest of the study.
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Figure 4.  IGF-1 signalling is enhanced by Rab7a siRNA knockdown in pancreatic islets. (a) Islets were 
transfected with 150 nM Rab7a siRNA or negative control siRNA, or left untransfected (UT). After 3 days, the 
cells were analysed by Western blot for β-tubulin and Rab7a expression. A representative blot is shown in (a) 
and quantification of Rab7a expression standardised to β-tubulin is shown in (b), where the graph shows n = 3 
data points from three independent experiments and the p value was calculated using Students’ t-test. (c, d) 
Show validation of the conditions required for ERK-1/2 phosphorylation in islets. Islets were culture overnight 
in low serum medium (0.5% FBS) then either stimulated with 0, 20 or 200 ng/ml IGF-1 for 7.5 min (c), or 
cultured with 200 ng/ml IGF-1 for the indicated times (d). Validation experiments in (c, d) were performed 
once to determine optimal conditions for subsequent experiments. In (e), islets were treated with 150 nM Rab7a 
siRNA or control siRNA, then cultured in low serum medium overnight before stimulation with 200 ng/ml 
IGF-1 for the indicated times. β-tubulin and p-ERK-1/2 expression were determined by Western blot. In (e) 
numbers under the blot indicate quantification of p-ERK-1/2 expression standardised to β-tubulin and relative 
to the untreated control, and the results are representative of two independent experiments. The graph in (f) is 
additional data from three further independent experiments showing the fold stimulation of phospho-ERK-1/2 
after 7.5 min treatment with 200 ng/ml IGF-1 relative to unstimulated control (n = 3).
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Figure 5.  Pancreatic islet survival is enhanced by Rab7a siRNA knockdown. Islets were transfected with Rab7a 
siRNA or negative control siRNA for 3 days, then dispersed into single cells by Accutase treatment and seeded 
onto poly-lysine coated coverslips in complete medium. Islet cells were then serum starved (0% FBS) for 12 h, 
then either treated with or without 200 ng/ml IGF-1. After 2 days, cells were treated with calcein AM (green live 
stain) and ethidium homodimer-1 (red dead stain) and imaged. Representative images of the overlaid channels 
are shown (a), and (b) shows the mean % live cells for n = 3 independent experiments. (c) Similar experiments 
were also performed with intact islets (without Accutase treatment). As an additional control in this experiment, 
control- and Rab7a-siRNA treated cells did not undergo serum starvation and were instead maintained in 10% 
FBS. Graph shows mean % live cells (n = 3). Statistical analysis was performed using Students’ t-test.
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Figure 6.  Rab7a attenuation protects against metabolic stress-induced beta cell death. INS-1 cells were treated 
with control- or Rab7a-siRNA for 3 days, then treated with the indicated concentration of palmitic acid (PA). (a) 
Cells were imaged using an IncucyteZoom system to determine cell area. (b) Representative images using 5 µM 
of Caspase-3/7 apoptosis reagent (Essen bioscience), which shows caspase-3/7 activation. Scale bar = 300 µm. (c) 
Cell lysates were prepared and analysed by western blot to quantify the amount of active (17 kDa) and inactive 
(35 kDa) Caspase-3. Representative blots are shown. (d) Relative mean expression of active caspase-3 is shown 
from three independent experiments. (e, f) Western blot analysis was used to determine expression of the 
autophagy marker LC3-I/II, with representative blots shown in (e), and relative mean expression of LC3-II from 
three independent experiments shown in (f). Values standardised to untreated control siRNA sample. Error bars 
indicate SEM, and Students’ t-test was used for statistical analysis.
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subjected to during diabetes pathogenesis. Targeting Rab7a therefore represents a novel potential therapeutic 
approach to promoting islet survival in type 2 diabetes patients.
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